Organogenesis Holdings Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
ORGO$0.91+11.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(amounts in thousands, except share and per share amounts)
| September 30, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $21,326 | $93,679 |
| Restricted cash | 163 | 652 |
| Accounts receivable, net | 92,687 | 217,451 |
| Inventories, net | 26,683 | 29,627 |
| Asset held for sale | — | 2,425 |
| Prepaid expenses and other current assets | 17,268 | 18,354 |
| Total current assets | 158,127 | 362,188 |
| Property and equipment, net | 98,600 | 103,711 |
| Intangible assets, net | 2,571 | 9,145 |
| Goodwill | 28,772 | 28,772 |
| Operating lease right-of-use assets, net | 47,808 | 55,749 |
| Deferred tax asset, net | — | 29,962 |
| Other assets | 33,027 | 9,203 |
| Total assets | $368,905 | $598,730 |
| Liabilities, Redeemable Convertible Preferred Stock, and Stockholders’ Equity | ||
| Current liabilities: | ||
| Current portion of finance lease obligations | $897 | $9,435 |
| Current portion of operating lease obligations - related party | 4,846 | 4,258 |
| Current portion of operating lease obligations | 3,569 | 4,949 |
| Accounts payable | 22,478 | 31,949 |
| Accrued expenses and other current liabilities | 15,859 | 49,533 |
| Total current liabilities | 47,649 | 100,124 |
| Finance lease obligations, net of current portion | 10,372 | 12,788 |
| Operating lease obligations, net of current portion - related party | 24,472 | 28,237 |
| Operating lease obligations, net of current portion | 20,360 | 22,470 |
| Other liabilities | 3,311 | 1,193 |
| Total liabilities | 106,164 | 164,812 |
| Commitments and contingencies (Note 15) | ||
| Series A redeemable convertible preferred stock, $0.0001 par value; 130,000 shares authorized, issued and outstanding; liquidation preference of $150,922 and $142,217 at September 30, 2026 and December 31, 2025, respectively. | 143,004 | 133,789 |
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 870,000 shares authorized; none issued or outstanding | — | — |
| Common stock, $0.0001 par value; 400,000,000 shares authorized; 130,522,276 and 127,680,424 shares issued; 129,793,728 and 126,951,876 shares outstanding at September 30, 2026 and December 31, 2025, respectively. | 13 | 13 |
| Additional paid-in capital | 302,164 | 303,194 |
| Accumulated deficit | (182,440) | (3,078) |
| Total stockholders’ equity | 119,737 | 300,129 |
| Total liabilities, redeemable convertible preferred stock, and stockholders' equity | $368,905 | $598,730 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.